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Atrazine belongs to the 2-chloro-s-triazine
family of herbicides (Figure 1) and is the most
common pesticide contaminant of ground-
water and surface water (Fenelon and Moore
1998; Kolpin et al. 1998; Lode et al. 1995;
Miller et al. 2000; Müller et al. 1997;
Solomon et al. 1996; Thurman and Cromwell
2000). Among the endocrine-disrupting
effects, atrazine interferes with androgen- and
estrogen-mediated processes (Babic-Gojmerac
et al. 1989; Cooper et al. 1999, 2000;
Cummings et al. 2000; Friedmann 2002;
Kniewald et al. 1979, 1995; Narotsky et al.
2001; Shafer et al. 1999; Simic et al. 1991;
Stoker et al. 1999, 2000). The interference of
atrazine with androgen and estrogen action
does not occur by direct agonism or antago-
nism of cognate receptors for these steroids as
shown by binding affinity studies (Roberge
et al. 2004; Tennant et al. 1994a, 1994b). In
this respect, previous investigations have sug-
gested that atrazine reduces androgen synthe-
sis and action (Babic-Gojmerac et al. 1989;
Kniewald et al. 1979, 1980, 1995; Simic et al.
1991) and stimulates estrogen production
(Crain et al. 1997; Heneweer et al. 2004;
Keller and McClellan-Green 2004; Sanderson
et al. 2000, 2001, 2002; Spano et al. 2004).
The latter ability is exerted through at least
two mechanisms that converge on increasing
aromatase expression and activity. First,
inhibiting phosphodiesterase, atrazine up-
regulates cAMP, which induces the expression
of SF-1, an important regulator of the PII
promoter of aromatase gene CYP19. The
enhanced transcription of the aromatase gene
increases both enzymatic activity of aromatase
and estrogen production (Heneweer et al.
2004; Lehmann et al. 2005; Morinaga et al.
2004; Roberge et al. 2004; Sanderson et al.
2000, 2001). Next, atrazine binds to SF-1 and
facilitates the recruitment of this factor to the
PII promoter of the aromatase gene, further
stimulating the biological effects described
above (Fan et al. 2007a, 2007b).
Epidemiologic studies have associated
long-term exposure to triazine herbicides with
increased risk of ovarian cancer in female farm
workers in Italy (Donna et al. 1989) and breast
cancer in the general population of Kentucky
in the United States (Kettles et al. 1997). In
addition, atrazine leads to tumor development
in the mammary gland and reproductive
organs of female F344 rats (Pintér et al. 1990),
whereas in Sprague-Dawley rats it causes an
earlier onset of mammary and pituitary tumors
(Wetzel et al. 1994), a typical response to
exogenously administered estrogens (Brawer
and Sonnenschein 1975).
Given the potential ability of atrazine to
interfere with reproduction and to cause can-
cer, the European Union banned its use.
However, the U.S. Environmental Protection
Agency has approved the use of atrazine
because of the lack of a clear association
between the levels of exposure and cancer
incidence in pesticide applicators (Gammon
et al. 2005; McElroy et al. 2007; Rusiecki
et al. 2004; Sass and Colangelo 2006; Young
et al. 2005).
Regarding the apparent estrogenic effects
of atrazine, previous studies have demonstrated
that triazine herbicides do not bind or activate
the classical estrogen receptor (ER) (Connor
et al. 1996; Tennant et al. 1994a, 1994b). In
recent years, increasing evidence has demon-
strated in different experimental models that
steroid hormones, including estrogens, can
exert rapid actions interacting with receptors
located within or near the cell membrane
(Falkenstein et al. 2000; Norman et al. 2004;
Revelli et al. 1998). The importance of this
signaling mechanism is becoming more widely
recognized as steroid membrane receptors have
been implicated in a large number of physio-
logic functions. Moreover, it has been sug-
gested that nongenomic estrogen actions, like
genomic ones, are susceptible to interference
from environmental estrogens (Thomas 2000).
Of note, these compounds compete with
[3H]17β-estradiol ([3H]E2) for binding to
estrogen membrane receptors (Loomis and
Thomas 2000) and exert agonist effects on
nongenomic transduction pathways in differ-
ent cell contexts (Loomis and Thomas 2000;
Nadal et al. 2000; Ruehlmann et al. 1988;
Watson et al. 1999). However, the precise
identity and function of many steroid mem-
brane receptors are still controversial in terms
of their specific molecular interactions with
endogenous and environmental estrogens.
A seven-transmembrane receptor, G-pro-
tein–coupled receptor 30 (GPR30), which is
structurally unrelated to the nuclear ER, has
been recently shown to mediate rapid actions
of estrogens (Filardo et al. 2002; Revankar
et al. 2005). Recombinant GPR30 protein,
produced in ER-negative HEK-293 cells,
exhibited all the steroid binding and signaling
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BACKGROUND: Atrazine, one of the most common pesticide contaminants, has been shown to
up-regulate aromatase activity in certain estrogen-sensitive tumors without binding or activating
the estrogen receptor (ER). Recent investigations have demonstrated that the orphan G-protein–
coupled receptor 30 (GPR30), which is structurally unrelated to the ER, mediates rapid actions
of 17β-estradiol and environmental estrogens.
OBJECTIVES: Given the ability of atrazine to exert estrogen-like activity in cancer cells, we evaluated
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METHODS AND RESULTS: Atrazine did not transactivate the endogenous ERα in different cancer cell
contexts or chimeric proteins encoding the ERα and ERβ hormone-binding domain in gene reporter
assays. Moreover, atrazine neither regulated the expression of ERα nor stimulated aromatase activity.
Interestingly, atrazine induced extracellular signal-regulated kinase (ERK) phosphorylation and the
expression of estrogen target genes. Using specific signaling inhibitors and gene silencing, we
demonstrated that atrazine stimulated the proliferation of ovarian cancer cells through the
GPR30–epidermal growth factor receptor transduction pathway and the involvement of ERα. 
CONCLUSIONS: Our results indicate a novel mechanism through which atrazine may exert relevant
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[Online 22 July 2008]characteristics of a functional estrogen mem-
brane receptor (Thomas et al. 2005; Thomas
and Dong 2006). Our studies and others have
also demonstrated that GPR30 mediates the
rapid response to E2 in a variety of estrogen-
responsive cancer cells by activating the epi-
dermal growth factor receptor (EGFR)–
mitogen-activated protein kinase (MAPK)
transduction pathway (Albanito et al. 2007;
Bologa et al. 2006; Filardo et al. 2000;
Maggiolini et al. 2004; Revankar et al. 2005;
Thomas et al. 2005; Vivacqua et al. 2006a,
2006b).
In the present study, for the ﬁrst time we
have demonstrated that atrazine stimulates
gene expression and growth effects in estrogen-
sensitive ovarian cancer cells through GPR30
and the involvement of ERα. Moreover, we
show that GPR30 mediates the stimulatory
effects of atrazine in ER-negative SkBr3 breast
cancer cells.
Materials and Methods
Reagents. We purchased atrazine [2-chloro-4-
(ethylamine)-6-(isopropylamine)-s-triazine],
17β-estradiol (E2), N-[2-(p-bromocinnamyl-
amino)ethyl]-5-isoquinolinesulfonamide
dihydrochloride (H89), wortmannin (WM),
and PD98059 (PD) from Sigma-Aldrich
(Milan, Italy); AG1478 (AG) from Biomol
Research Laboratories (DBA, Milan, Italy);
ICI 182,780 (ICI) from Tocris Chemicals
(Bristol, UK); and GF109203X (GFX) from
Calbiochem (VWR International, Milan,
Italy). All compounds were solubilized in
dimethyl sulfoxide (DMSO), except E2 and
PD, which were dissolved in ethanol.
Cell culture. Human BG-1 and 2008 ovar-
ian cancer cells as well as human Ishikawa
endometrial cancer cells were maintained in
phenol red–free Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10%
fetal bovine serum (FBS). H295R adrenal carci-
noma cells were cultured in DMEM/F12 1:1
supplemented with 1% ITS Liquid Media
Supplement (Sigma-Aldrich), 10% calf serum,
and antibiotics. Human MCF-7 breast cancer
cells were maintained in DMEM with phenol
red supplemented with 10% FBS, and human
SkBr3 breast cancer cells were maintained in
phenol red–free RPMI 1640 supplemented
with 10% FBS. Cells were switched to medium
without serum the day before experiments
for immunoblots and reverse transcription-
polymerase chain reaction (RT-PCR).
Plasmids. Firefly luciferase reporter plas-
mids used were XETL for ERα (Bunone et al.
1996) and GK1 for yeast transcription factor
Gal4 fusion proteins (Webb et al. 1998).
XETL contains the estrogen response element
(ERE) from the Xenopus vitellogenin A2 gene
(nucleotides –334 to –289), the herpes simplex
virus thymidine kinase promoter region
(nucleotides –109 to +52), the ﬁreﬂy luciferase
coding sequence, and the SV40 splice and
polyadenylation sites from plasmid pSV232A/
L-AA5. Gal4 chimeras Gal-ERα and Gal-ERβ
were expressed from plasmids GAL93.ER(G)
and GAL.ERβ, respectively. They were con-
structed by transferring the coding sequences
for the hormone-binding domain (HBD) of
ERα (amino acids 282–595) from HEG0
(Bunone et al. 1996), and for the ERβ HBD
(C-terminal 287 amino acids) from plasmid
pCMV5-hERβ into the mammalian expres-
sion vector pSCTEVGal93 (Seipel et al. 1992).
We used the Renilla luciferase expression
vector pRL-TK (Promega, Milan, Italy) as a
transfection standard.
Transfection and luciferase assays. BG-1,
MCF-7, Ishikawa, and SkBr3 cells (1 × 105)
were plated into 24-well dishes with
500 µL/well DMEM (BG-1, MCF-7, and
Ishikawa cells) or RPMI 1640 (SkBr3 cells)
containing 10% FBS the day before transfec-
tion. We replaced the medium with phenol
red–free DMEM or RPMI 1640, both sup-
plemented with 1% charcoal-stripped (CS)
FBS, on the day of transfection. Transfections
were performed using FuGENE 6 Reagent as
recommended by the manufacturer (Roche
Diagnostics, Mannheim, Germany) with a
mixture containing 0.3 µg of reporter plas-
mid, 1 ng pRL-TK, and 0.1 µg effector plas-
mid where applicable. After 5–6 hr, the
medium was replaced again with serum-free
DMEM lacking phenol red and supple-
mented with 1% CS-FBS; ligands were added
at this point, and cells were incubated for
16–18 hr. We measured luciferase activity
with the Dual Luciferase Kit (Promega)
according to the manufacturer’s recommen-
dations. Fireﬂy luciferase values were normal-
ized to the internal transfection control
provided by Renilla luciferase activity. The
normalized relative light unit values obtained
from cells treated with vehicle were set as
1-fold induction, from which the activity
induced by treatments was calculated.
RT-PCR. Using semiquantitative RT-PCR
as described previously (Maggiolini et al.
1999), we evaluated gene expression for ERα
[GenBank accession no. NM 000125 (National
Center for Biotechnology Information 2008)],
c-fos (NM 005252), progesterone receptor
(PR; NM 000926), pS2 (NM 003225),
cathepsin D (NM 001909), cyclin A (NM
001237), cyclin D1 (NM 053056), cyclin E
(NM 001238), and the acid phosphoprotein
P0 (36B4) (NM 001002) used as a control
gene. We used the primers 5´-AATTCA-
GATAATCGACGCCAG-3´ (ERα forward)
and 5´-GTGTTTCAACATTCTCCCTC-
CTC-3´ (ERα reverse); 5´-AGAAAAGGA-
GAATCCGAAGGGAAA-3´ (c-fos forward)
and 5´-ATGATGCTGGGACAGGAAG-
TC-3´ (c-fos reverse); 5´-ACACCTTGC-
CTGAAGTTTCG-3´ (PR forward) and
5´-CTGTCCTTTTCTGGGGGACT-3´
(PR reverse); 5´-TTCTATCCTAATAC-
CATCGACG-3´ (pS2 forward) and
5´-TTTGAGTAGTCAAAGTCAGAGC-3´
(pS2 reverse); 5´-AACAACAGGGTG
GGCTTC-3´ (cathepsin D forward), and
5´-ATGCACGAAACAGATCTGTGCT-3´
(cathepsin D reverse); 5´-GCCATTAGTT-
TACCTGGACCCAGA-3´ (cyclin A for-
ward) and 5´-CACTGACATGGAAGACAG
GAACCT-3´ (cyclin A reverse); 5´-TCTAA-
GATGAAGGAGACCATC-3´, (cyclin D1
forward) and 5´-GCGGTAGTAGGACAG
GAAGTTGTT-3´ (cyclin D1 reverse);
5´-CCTGACTATTGTGTCCTGGC-3´
(cyclin E forward) and 5´-CCCGCT-
GCTCTGCTTCTTAC-3´ (cyclin E reverse);
and 5´-CTCAACATCTCCCCCTTCTC-3´
(36B4 forward) and 5´-CAAATCCCA-
TATCCTCGTCC-3´ (36B4 reverse) to yield
products of 345, 420, 196, 210, 303, 354,
354, 488, and 408 bp, respectively, with
20 PCR cycles for ERα, c-fos, PR, pS2, cathep-
sin D, cyclin A, and cyclin E and 15 PCR
cycles for both cyclin D1 and 36B4.
Western blotting. Cells were grown in
10-cm dishes, exposed to ligands, and then
lysed in 500 µL of 50 mmol/L NaCl, 1.5
mmol/L MgCl2, 1 mmol/L EGTA, 10%
glycerol, 1% Triton X-100, 1% sodium dode-
cyl sulfate (SDS), and a mixture of protease
inhibitors containing 1 mmol/L aprotinin,
20 mmol/L phenylmethylsulfonyl ﬂuoride, and
200 mmol/L sodium orthovanadate. We then
diluted samples 10 times and determined pro-
tein concentration using Bradford reagent
according to the manufacturer’s recommenda-
tions (Sigma-Aldrich). Equal amounts of whole
protein extract were resolved on a 10% SDS-
polyacrylamide gel and transferred to a nitro-
cellulose membrane (Amersham Biosciences,
Milan, Italy). Membranes were probed
overnight at 4°C with the antibody against
ERα (F-10), c-fos (H-125), β-actin (C-2),
phosphorylated extracellular signal-regulated
kinase 1/2 (ERK1/2; E-4), and ERK2 (C-14),
all purchased from Santa Cruz Biotechnology,
DBA (Milan, Italy), and human P450 aro-
matase (MCA 2077S; Serotec, Milan, Italy),
and then revealed using the ECL Western
Blotting Analysis System (GE Healthcare,
Milan, Italy).
ER binding assay. BG-1 cells were stripped
of any estrogen by keeping them in medium
without serum for 2 days. Cells were incubated
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Figure 1. Structures of E2 and atrazine.
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E2 Atrazinewith 1 nM [2,4,6,7-3H]E2 (89 Ci/mmol;
Amersham Biosciences) and increasing concen-
trations of nonlabeled E2 or atrazine for 1 hr at
37°C in a humidified atmosphere of 95%
air/5% CO2. After removal of the medium,
cells were washed with ice-cold phosphate-
buffered saline/0.1% methylcellulose twice,
harvested by scraping and centrifugation, and
lysed with 100% ethanol, 500 µL/60-mm
dish, for 10 min at room temperature (Lee and
Gorski 1996). We measured the radioactivity
of extracts by liquid scintillation counting.
Aromatase assay. In subconﬂuent BG-1 or
H295R cells, we measured aromatase activity
in the cell culture medium by tritiated water
release using 0.5 µM [1β-3H(N)]androst-4-
ene-3,17-dione (25.3 Ci/mmol; DuPont
NEN, Boston, MA, USA) as a substrate
(Lephart and Simpson 1991). The cells were
treated in a six-well dish in culture medium in
the presence of atrazine or DMSO for 40 hr
and then incubated with [1β-3H(N)]androst-
4-ene-3,17-dione. Incubations were per-
formed at 37°C for 6 hr under a 95%/5%
air/CO2 atmosphere. The results were calcu-
lated as picomoles per hour, normalized to
milligrams of protein (pmol/hr per 1 mg pro-
tein), and expressed as percentages of
untreated cells (100%).
GPR30 and ERα silencing experiments.
Cells were plated onto 10-cm dishes, main-
tained in antibiotic-free medium for 24 hr,
and then transfected for additional 24 hr
before treatments with a mixture containing
Opti-MEM, 8 µL/well LipofectAMINE 2000
(Invitrogen, Milan, Italy), and 0.5 µg/well
vector or short hairpin GPR30 (shGPR30)
(Albanito et al. 2008), control small inter-
fering RNA (siRNA), or ERα siRNA (Sigma-
Aldrich). 
Proliferation assay. For the quantitative
proliferation assay, we seeded 10,000 cells in
24-well plates in regular growth medium. Cells
were washed once they had attached and then
incubated in medium containing 2.5%
CS-FBS with the indicated treatments.
Medium was renewed every 2 days (with treat-
ments), and cells were trypsinized and counted
in a hemocytometer on day 6. The day before
treatments, 200 ng/L of the indicated short
hairpin RNA was transfected using FuGENE 6
Reagent as recommended by the manufacturer,
and then renewed every 2 days before counting.
Statistical analysis. Statistical analysis was
performed using analysis of variance followed
by Newman-Keuls testing to determine dif-
ferences in means. p-Values < 0.05 are consid-
ered statistically signiﬁcant.
Results
Atrazine does not activate ERα in cancer cells.
Based on the evidence that atrazine produces
early onset and increased incidence of estro-
gen-sensitive tumors in different experimental
models (Cooper et al. 2007), we ﬁrst evaluated
whether atrazine could activate a transiently
transfected ER reporter gene in estrogen-sensi-
tive ovarian (BG-1), breast (MCF-7), and
endometrial (Ishikawa) cancer cells. Exposure
to 100 nM E2 induced a strong ERα transacti-
vation that was absent in the presence of
10 µM of the ER antagonist ICI in all cell
contexts evaluated (Figure 2A–C). In contrast,
treatments with 1 µM atrazine and even con-
centrations ranging from 1 nM to 10 µM
(data not shown) failed to stimulate luciferase
expression or to block that observed upon
addition of E2 (Figure 2A–C). Moreover,
atrazine did not activate an expression vector
encoding ERα transiently transfected in ER-
negative SkBr3 breast cancer cells (Figure 2D).
To conﬁrm that atrazine is not an ERα ago-
nist and to examine whether ERβ could
respond to atrazine, we turned to a completely
heterologous system. Chimeric proteins con-
sisting of the DNA binding domain of the
yeast transcription factor Gal4 and the ERα or
ERβ HBD transiently transfected in SkBr3
Albanito et al.
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Figure 2. ERα transactivation in BG-1 (A), MCF-7 (B), and Ishikawa (C) cells transfected with the ER
luciferase reporter plasmid XETL (ERE-luc) and treated with 100 nmol/L E2 or 1 μmol/L atrazine (Atr), with
and without 10 μmol/L ER antagonist ICI. Luciferase activities were normalized to the internal transfection
control, and values of cells receiving vehicle (–) were set as 1-fold induction, from which the activity
induced by treatments was calculated. (D–F) SkBr3 cells were transfected with ER luciferase reporter
gene XETL and ERα expression plasmid (D) and with Gal4 reporter gene (GK1) and the Gal4 fusion proteins
encoding the HBD of ERα (GalERα; E) and or ERβ (GalERβ; F) and treated with 100 nmol/L E2 or 1 μmol/L
atrazine, with and without 10 μmol/L ICI. Values shown are mean ± SD of three independent experiments
performed in triplicate. 
*p < 0.05 compared with vehicle. 
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Figure 3. mRNA expression and binding of ERα in BG-1 cells treated for 24 hr with vehicle (–), 100 nmol/L
E2, or 1 μmol/L atrazine (Atr). (A) mRNA expression of ERα was evaluated by semiquantitative RT-PCR; the
values of housekeeping gene 36B4 were determined as a control. (B) Immunoblot of ERα from BG-1 cells,
with 100 nmol β-actin serving as a loading control. Results in (A) and (B) are representative of three inde-
pendent experiments. (C) ERα binding assay using increasing concentrations of atrazine. 
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mRNAcells were strongly activated by E2 but not
upon atrazine treatment (Figure 2E,F), further
corroborating the aforementioned results.
Atrazine neither regulates ERα expression
nor competes with estrogen binding to ERα.
Considering that the down-regulation of ERα
induced by an agonist has been considered an
additional hallmark of receptor activation
(Santagati et al. 1997), we further investigated
whether atrazine could modulate ERα expres-
sion in BG-1 cells, which lack ERβ (data not
shown), and express a receptor expression pat-
tern similar to that found in primary ovarian
tumors (Bardin et al. 2004; Geisinger et al.
1989). As shown in Figure 3A,B, 100 nM E2
down-regulated ERα at both mRNA and
protein levels, whereas 1 µM atrazine did not
produce any modulatory effect. In agreement
with these results and those obtained in trans-
fection experiments, atrazine showed no bind-
ing capacity for ERα (Figure 3C), as previously
reported (Cooper et al. 2007). Altogether, our
findings rule out that the estrogen action of
atrazine occurs through binding and direct
activation of ERα.
Aromatase activity is not induced by
atrazine. Given that atrazine is able to up-
regulate aromatase expression and function in
different cell contexts (Cooper et al. 2007;
Fan et al. 2007a, 2007b; Roberge et al. 2004;
Sanderson et al. 2000, 2001), we then deter-
mined aromatase activity by tritiated water
release assays in BG-1 cells. As shown in
Figure 4, 1 µM atrazine did not stimulate aro-
matase activity, which in contrast was
strongly induced in human H295R adreno-
corticocarcinoma cells previously used as a
model system to assess aromatase catalytic
activity (Heneweer et al. 2004; Sanderson
et al. 2001). In addition, the low aromatase
protein expression detected in BG-1 cells did
not increase upon exposure to 1 µM atrazine
(data not shown). Hence, atrazine is neither
an ERα activator nor an aromatase regulator
in estrogen-sensitive ovarian cancer cells.
ERK phosphorylation is stimulated by
atrazine. In recent years, numerous reports
have demonstrated that estrogens and xeno-
estrogens can generate rapid signaling via sec-
ond messenger systems such as Ca2+, cAMP,
nitric oxide, and G-proteins, which in turn
leads to activation of different downstream
kinases (Bulayeva and Watson 2004; Watson
et al. 2007).
To evaluate whether the potential estro-
genic activity of atrazine is exerted through a
rapid cellular response, we investigated its
ability to produce ERK phosphorylation in
BG-1 cells. Interestingly, atrazine stimulated
ERK phosphorylation, although a higher con-
centration and prolonged time period were
required to trigger this biochemical response
compared with E2 (Figures 5A,B, 6A). ERK
activation was also delayed in the presence of
1 µM atrazine compared with 100 nM E2 in
2008 ovarian cancer cells (Figure 6D), which
present a receptor expression similar to that of
BG-1 cells (Safei et al. 2005). To determine
the transduction pathways involved in ERK
activation by atrazine, cells were exposed to
100 nM E2 and 1 µM atrazine along with
speciﬁc inhibitors widely used to pinpoint the
mechanisms contributing to ERK phosphory-
lation (Bulayeva and Watson 2004). Of note,
the ER antagonist ICI, the EGFR inhibitor
AG and the ERK inhibitor PD prevented
ERK activation induced by both E2 and
atrazine, whereas GFX, H89, and WM,
inhibitors of protein kinase C (PKC), protein
kinase A (PKA), and phosphoinositide
3-kinase (PI3K), respectively, did not
(Figure 6B,C,E,F). Considering that in a pre-
vious study ICI was able to trigger ERK phos-
phorylation (Filardo et al. 2000), we exposed
SkBr3 cells to increasing concentrations of
ICI. We observed no ERK activation after
Atrazine action in ovarian cancer cells
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Figure 4. Aromatase activity assessed by tritiated
water release in BG-1 and H295R cells treated with
vehicle (–) or 1 μmol/L atrazine (Atr). Results are
expressed as percentages of untreated cells
(100%). Values are mean ± SD of three independent
experiments, each performed in triplicate. 
*p < 0.05 compared with vehicle. 
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Figure 5. ERK1/2 phosphorylation (pERK1/2) in BG-1
cells exposed to increasing concentrations of E2 or
atrazine (Atr) for 20 min. 
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Figure 6. BG-1 (A–C) and 2008 (D–F) cells treated with vehicle (–) or 100 nmol/L E2 with or without 1 μmol/L
atrazine (Atr) for 5, 10, 20, or 30 min (A,D), or for 20 min with vehicle E2 (B and E), or 1 μmol Atr in combina-
tion with 10 μmol/L ICI, AG, PD, GFX, H89, or WM, inhibitors of ER, EGFR, MEK (MAP/ERK kinase), PKC (pro-
tein kinase C), PKA (protein kinase A), and PI3K (phosphoinositide 3-kinase), respectively. pERK1/2,
phosphorylated ERK 1/2. 
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Feither 5 min (data not shown) or 20 min of
treatment (Figure 7). Hence, in our experi-
mental conditions, ICI showed only ERK
inhibitor activity.
Atrazine up-regulates the mRNA expression
of estrogen target genes. Having determined that
atrazine signals through a rapid ERK activation,
we evaluated in BG-1 cells its ability to regulate
the expression of c-fos, an early gene that
responds to a variety of extracellular stimuli,
including estrogens (Maggiolini et al. 2004;
Nephew et al. 1993; Singleton et al. 2003;
Vivacqua et al. 2006ab), along with other estro-
gen target genes. To this end, we performed
semiquantitative RT-PCR experiments com-
paring mRNA levels after standardization with
a housekeeping gene encoding the ribosomal
protein 36B4. A short treatment (1 hr) with
1 µM atrazine enhanced c-fos and cyclin A lev-
els, although to a lesser extent than 100 nM E2,
which also stimulated PR, pS2, and cyclin D1
expression (Table 1). After a 24-hr treatment,
atrazine increased PR, pS2, and cyclin A levels,
whereas E2 additionally induced the expression
of c-fos, cathepsin D, cyclin D1, and cyclin E
(Table 1). We obtained results similar to those
described above in 2008 cells (data not shown).
Hence, atrazine is able to stimulate the expres-
sion of diverse estrogen target genes without an
apparent activation of ERα. 
Transduction pathways involved by
atrazine in the up-regulation of c-fos protein
levels. Using c-fos expression as a molecular sen-
sor of atrazine action at the genomic level, we
sought to determine whether c-fos protein levels
are also regulated by atrazine in a rapid manner
and the transduction pathways involved in this
response (Figure 8). Interestingly, the up-
regulation of c-fos observed in BG-1 and 2008
cells after a short treatment (2 hr) was abolished
by the ER antagonist ICI, the EGFR inhibitor
AG, or the ERK inhibitor PD (Figure 8). On
the contrary, GFX, H89, and WM, inhibitors
of PKC, PKA, and PI3K, respectively, did not
interfere with c-fos stimulation (Figure 8).
Thus, in ovarian cancer cells, atrazine involves
ERα and the EGFR/MAPK pathway to trigger
c-fos protein increase. 
On the basis of these and our previous
results showing that c-fos stimulation by E2
occurs through GPR30 and requires ERα and
EGFR-mediated signaling in cancer cells
expressing both receptors (Albanito et al. 2007;
Maggiolini et al. 2004; Vivacqua et al. 2006a,
2006b), we examined whether atrazine could
act in a similar manner. Interestingly, both E2
and atrazine were no longer able to induce c-fos
Albanito et al.
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Figure 9. Immunoblots of c-fos from BG-1 (A,B) and 2008 (C,D) cells after silencing ERα and GPR30 expres-
sion. Cells were transfected with control siRNA or siRNA-ERα (A,C) or with vector or shGPR30 (B,D) and
treated for 2 hr with vehicle (–) or 100 nmol/L E2 or 1 μmol/L atrazine (Atr). Efficacy of ERα and GPR30
silencing was ascertained by immunoblots, as shown in side panels. β-Actin served as a loading control. 
Figure 8. Immunoblots of c-fos from BG-1 (A,B) and 2008 (C,D) cells treated for 2 hr with vehicle (–),
100 nmol/L E2, or 1 μmol/L atrazine (Atr) in combination with 10 μmol/L ICI, AG, PD, GFX, H89, or WM,
inhibitors of ER, EGFR, MEK, PKC, PKA, and PI3K, respectively. β-Actin served as a loading control. 
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Figure 7. ERK1/2 phosphorylation (pERK1/2) in SkBr3
cells treated for 20 min with vehicle (–) or increas-
ing concentrations of ICI. 
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Table 1. mRNA expression (mean percent variation
± SD) induced by 100 nM E2 and 1 μM atrazine in
BG-1 cells.
E2 Atrazine
Gene 1 hr 24 hr 1 hr 24 hr
c-fos 423 ± 28* 239 ± 17* 269 ± 21* 120 ± 9
PR 228 ± 18* 298 ± 18* 122 ± 18 180 ± 11*
pS2 175 ± 17* 270 ± 21* 99 ± 19 187 ± 20*
Cathepsin D 106 ± 9 217 ± 16* 102 ± 5 109 ± 6
Cyclin A 262 ± 22* 293 ± 23* 220 ± 20* 190 ± 22*
Cyclin D1 258 ± 19* 242 ± 19* 107 ± 4 118 ± 8
Cyclin E 120 ± 11 343 ± 21* 118 ± 8 119 ± 10 
The values calculated by optical density in cells treated
with vehicle were set at 100%, and the expression induced
by treatments is presented as percent variation. 
*p < 0.05 compared with vehicle.
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Dexpression after silencing either ERα or
GPR30 in BG-1 and 2008 cells (Figure 9). To
evaluate whether atrazine could induce a rapid
response in a cell context expressing GPR30
alone, we turned to ER-negative SkBr3 breast
cancer cells. Notably, both ERK phosphoryla-
tion and c-fos induction stimulated by atrazine
were abolished after silencing GPR30
(Figure 10), indicating that the response to
atrazine is differentially regulated according to
cancer cell type.
The proliferation of ovarian cancer cells
induced by atrazine occurs through GPR30
and requires both ERα and EGFR/MAPK-
mediated signaling. The aforementioned
results were recapitulated in a more complex
physiologic assay such as cell growth. We
observed that both E2 and atrazine induced the
proliferation of BG-1 and 2008 cells in a con-
centration-dependent manner (Figure 11A,E).
Moreover, the growth effects elicited by E2 and
atrazine were no longer evident in the presence
of AG and PD (Figure 11B,F) or after silenc-
ing the expression of either GPR30 or ERα
(Figure 11C,D,G,H), indicating that both
receptors, along with the EGFR/MAPK trans-
duction pathway, are involved in the growth
effects as well as in the c-fos expression proﬁle
described above.
Discussion
In the present study, we demonstrated for the
ﬁrst time that atrazine exerts an estrogen-like
activity in ovarian and breast cancer cells
through GPR30, which is recently of interest
because of its ability to mediate rapid estrogen
signals (Albanito et al. 2007, 2008; Filardo
et al. 2006, 2007; Revankar et al. 2005,
2007).
Previous studies have demonstrated that
atrazine elicits estrogen action by up-regulat-
ing aromatase activity in certain cancer cells
with elevated aromatase levels (Fan et al.
2007a, 2007b; Heneweer et al. 2004;
Sanderson et al. 2000, 2001) but not by bind-
ing to or activating ERα (Connor et al. 1996;
Roberge et al. 2004; Tennant 1994a). Using
different tumor cells and reporter genes, we
confirmed that atrazine did not interact
directly with ERα, yet it did not stimulate
aromatase activity in our model system, likely
as a consequence of a very low aromatase
expression. Nevertheless, atrazine induced the
expression of diverse estrogen target genes,
recalling previous studies that demonstrated
the recruitment of ERα by distinct com-
pounds and growth factors to gene promoter
sequences different from the classical estrogen
response element (reviewed by Dudek and
Picard 2008).
Interestingly, we showed that GPR30 and
ERα, together with the EGFR/MAPK path-
way, are involved in the biological response to
atrazine in ovarian cancer cells, which is in
accordance with our recent investigation show-
ing that the selective GPR30 ligand G-1 exerts
biological activity similar to that of atrazine
without binding or activating ERα (Albanito
et al. 2007). Hence, our data indicate that a
complex interplay between different ERs and
transduction pathways contributes to atrazine
activity, which nevertheless is still noticeable in
the presence of GPR30 alone, as demonstrated
in SkBr3 breast cancer cells. Although E2
exhibited an exclusive up-regulation of target
genes through direct activation of ERα, the
GPR30–EGFR transduction pathway was
involved in estrogen-induced proliferation of
ovarian tumor cells, as evidenced by silencing
GPR30 and using specific pharmacologic
inhibitors.
A variety of environmental contaminants
exhibit binding afﬁnities for GPR30 and ago-
nist activities similar to those for ERs
(Thomas and Dong 2006). In the present
study atrazine triggered rapid biological
responses through GPR30 in both ovarian
and breast cancer cells irrespective of ERα
expression and despite a low binding afﬁnity
for GPR30 ectopically expressed in HEK-293
cells (Thomas and Dong 2006). In line with
these findings, an efficient competitor of E2
for endogenous GPR30 in SkBr3 cells, such
as an ortho,para-dichlorodiphenyldichloro-
ethylene (DDE) derivative, was ineffective in
binding to recombinant GPR30 (Thomas
et al. 2005; Thomas and Dong 2006). Likely,
the interaction of atrazine with GPR30 is
facilitated by the relative abundance of this
membrane receptor in cancer cells with
respect to cells engineered to express recombi-
nant GPR30, and/or yet unknown factors
may contribute to the binding to GPR30 by
these contaminants.
Regarding the role of ERα, we proved
that a complex interplay with GPR30 exists,
as previously reported with some growth fac-
tor receptors (Migliaccio et al. 2006), but the
Atrazine action in ovarian cancer cells
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Figure 10. ERK1/2 phosphorylation (A) and c-fos
expression (B) after silencing GPR30 in SkBr3 cells
treated with vehicle (–) or 1 μmol/L atrazine (Atr). (C)
The efﬁcacy of GPR30 silencing was ascertained by
immunoblots. β-Actin served as a loading control. 
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Figure 11. Proliferation of BG-1 (A–D) and 2008 (E–H) cells exposed to E2 or atrazine (Atr). (A,D) Proliferation
of cells in response to increasing concentrations of E2 or Atr. (B–H) Proliferation of cells treated with vehi-
cle (–), 100 nmol/L E2, or 1 μmol/L Atr with or without 10 μmol/L AG or PD (B,F) (C,D, G, H) or transfected with
vector or shGPR30 (C,G) or with control siRNA or siRNA-ERα (D,H). See “Materials and Methods” for details
of experiments. Proliferation of cells receiving vehicle was set as 100%, and the cell growth induced by
treatments was calculated. Values shown are mean ± SD of three independent experiments performed in
triplicate; Efﬁcacy of ERα and GPR30 silencing was ascertained by immunoblots (Figure 9). 
*p < 0.05 compared with treated cells. 
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*molecular mechanisms involved remain to be
elucidated. Our study and previous investiga-
tions indicate that environmental estrogens
exert pleiotropic actions by directly binding
to ERα as well as through GPR30–EGFR
signaling, which can engage ERα depending
on the receptor expression pattern present in
different cell types. This mode of action of
xenoestrogens fits well with the results
obtained after silencing GPR30 or ERα
expression in ovarian cancer cells, because
silencing each gene prevented the growth
response to atrazine.
Our data recall the results of previous
studies showing that xenoestrogens mimic
rapid estrogen action in several animal and cell
models (Bulayeva and Watson 2004; Loomis
and Thomas 2000; Nadal et al. 2000;
Ruehlmann et al. 1988; Watson et al. 1999,
2007). Particularly, in GH3/B6/F10 pituitary
tumor cells, diverse xenoestrogens induced
ERK phosphorylation with a temporally dis-
tinct activation pattern compared with E2
(Bulayeva and Watson 2004). In the latter
study, on the basis of the inhibitory activity
exerted by ICI, the authors hypothesized that
an ER localized to the plasma membrane
could mediate the ERK phosphorylation
response by xenoestrogens, depending on their
different ER binding afﬁnities. Moreover, the
authors suggested that the signaling cascades
leading to ERK activation may involve the
nature of membrane ERs and their ability to
interact with various signaling partners
(Bulayeva and Watson 2004). Interestingly,
our ﬁndings have provided evidence that ERα
may be involved by xenoestrogens without a
direct binding activity and produce relevant
responses such as ERK phosphorylation, gene
expression, and cell growth.
A subset of estrogen-sensitive cell tumors
can proliferate independently from ER expres-
sion (i.e., ER-negative cells). In this condition,
well represented by SkBr3 breast cancer cells,
GPR30–EGFR signaling may still allow for
environmental estrogen activity as we have
shown in the present study as well as in a pre-
vious study (Maggiolini et al. 2004). Hence,
multiple transduction pathways triggered
simultaneously at the membrane level, as well
as within each cell type, may contribute to the
nature and magnitude of biological responses
to distinct estrogenic compounds. These con-
sequently should be examined individually for
their complex mechanistic and functional out-
comes that result from interaction with a dif-
ferent repertoire of receptor proteins.
Atrazine, a potent endocrine disruptor, is
the most common pesticide contaminant of
groundwater and surface water. Here, we have
provided novel insight regarding the potential
role of GPR30 in mediating the action of
atrazine in endocrine-related diseases, such as
estrogen-sensitive tumors.
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